On the other hand, failure of DDR is a weakness that can be targeted therapeutically, as in the case of the PARP inhibitor, Olaparib, an inhibitor that has shown considerable promise in patients with several cancer types harboring germline mutations in BRCA1/2, including ovarian, breast and pancreatic cancers [21–23]. This evidence concerns the gene BRCA1 and cancer.